Contaminated Blood — House of Commons, 2017-07-11
Topic: Health
Philippa Whitford (Scottish National Party, Centre-left): The inquiry will have to look at all those things. Documents, patients’ records, things that were altered and hidden, and things that are hiding behind public interest barriers now all need to be opened up so that light can be shed on the matter, as with Hillsborough Penrose was a Scotland-only inquiry. The Department of Health was invited to take part and turn it into a UK-wide inquiry, but it declined. One of the key weaknesses of the inquiry was that Penrose did not have the right to summon documents or people I remember when the scandal started to unfold in the ’80s. As a surgeon who was, of course, using blood on her patients, I remember how shocked I was at the mere thought that an action I might have taken could have harmed a patient I was looking after. In my elective surgery, I set about chasing every single blood cell to avoid spilling blood. I used electrocautery and all sorts of modern techniques. If I were to wheel out the staff from my theatre now, they would moan about how long I used to spend doing that. If a clinician is dealing with someone who has been hit by a bus, however, they have no choice I remember a critic of Penrose in 2015 saying that they were surprised that clinicians showed so much trust in the quality of blood, but a clinician who is using hundreds of drugs, implants, machines and blood products must be able to trust them. We have no mechanism personally to check them. That is the role of the Government and all their agencies. It is why we have licensing and inspections, and it is why action must be taken when there is a suspicion of harm. Failing to act, hiding and not dealing with the situation at the time all happened pre-devolution, and this inquiry must take account of that At a conference in Glasgow in 1980, clinicians were already raising concerns about changes in the liver function of patients who were receiving blood concentrate for haemophilia. A 1981 meeting of the UK’s Blood Transfusion Research Committee, which we have all read about recently, recognised that about 50 patients a year developed some form of liver damage. Yet the decision at that meeting appeared to be to let that continue and simply to study the situation, using those patients as a way of developing a test for what was known at the time as non-A, non-B hepatitis. It is important that we ensure that this inquiry looks at all this. The official from the Department of Health and Social Security who was at that meeting would not attend Penrose. Such people need to be called by this inquiry Going forward, the inquiry must include the families and the victims so that we are sensitive to what they want to know. This is also about not just the Government but producers—and not just producers in America. We try to make ourselves feel better by blaming this on the States, where people bought blood, and where people with addictions, people living in poverty and prisoners were used. In the mid-70s, prisoners in this country were also used, and it is claimed that that was encouraged by the Home Office as part of prisoner rehabilitation. We need the documents on that; we need to understand if that decision was made. UK producers have often been found wanting in the quality of product they came up with, so we must not pat ourselves on the back and imagine that the UK product was somehow safe and that this was all due to the US. We need to follow this right down and get the answers These people have been failed so many times, over and over, and it is crucial that that does not happen again. We need to keep the Government on their toes. We need to have reports back from this inquiry as it is set up, so that we know what it is actually going to look into. If we fail to get answers this time, and particularly if we fail to deliver compensation for the lives lost, the suffering, the failure to get a mortgage or insurance, and the costs of care, we will have failed these people all over again.